...
首页> 外文期刊>Oncology letters >Clinical research on alternating hyperfraction radiotherapy for massive hepatocellular carcinoma
【24h】

Clinical research on alternating hyperfraction radiotherapy for massive hepatocellular carcinoma

机译:巨细胞肝癌交替超分割放疗的临床研究

获取原文
获取原文并翻译 | 示例

摘要

The delivery of high tumoricidal doses of radiation with low rates of toxicity is of particular significance for massive hepatocellular carcinoma (HCC) radiotherapy. In order to observe the efficacy and adverse reactions of alternating hyperfraction radiotherapy treatment of massive HCC, seventy-two cases of massive HCC were randomly divided into two groups, group A and group B. The liver lesions of group A were divided into sublesions and treated with alternating hyperfraction radiotherapy [intensity modulated radiotherapy (IMRT)]. The interval between radiotherapy to the sublesions was a minimum of six hours. The average radiotherapy dose to the sublesions was 2 Gy/fraction, once a day, five times per week, treating the gross tumor volume with a total dose of 40-50 Gy, and the clinical target volume with a total dose of 30-40 Gy. By contrast, the lesions of group B were not divided into sublesions for the IMRT treatment, but were treated with an otherwise identical protocol, by 2 Gy/fraction, once a day, five times per week, and with the same total dose. Patients were followed up with regular blood tests, liver function tests, measurements of serum -fetoprotein levels and contrast-enhanced magnetic resonance imaging (MRI) of the liver. Treatment responses were assessed every 3 months by MRI. The results revealed that the overall response rates of the two groups were 82.9 and 81.3%, respectively (P=0.864). The alternating hyperfraction radiotherapy protocol resulted in enhanced survival (P=0.002). The median survival time of the two groups was 9.7 and 6.5 months, respectively. The overall 6-month, 1-year, 2-year and 3-year survival rates of the two groups were 62.9 and 59.4% (P=0.770), 48.6 and 21.9% (P=0.040), 17.1 and 0.0% (P=0.025) and 2.9 and 0.0% (P=1.000), respectively. The I-II degree of abnormal liver function and radiation-induced liver disease of group B was higher than that of group A (P=0.021 and 0.046, respectively). In addition, the incidence rate of radiation-induced liver injury of group A was lower than that of group B. Therefore, treatment of massive HCC with alternating hyperfraction radiotherapy improved the quality of life and prolonged the overall survival time, compared with conventional IMRT, suggesting that it was an effective radiation pattern.
机译:对于大规模肝细胞癌(HCC)放射治疗,高剂量,低毒性的高剂量放射治疗尤其重要。为观察交替超分割放疗治疗重型肝癌的疗效和不良反应,将72例重型肝癌随机分为两组,即A组和B组。交替超分割放疗[强度调制放疗(IMRT)]。放疗至皮损的间隔至少为六个小时。对皮损的平均放疗剂量为2 Gy /分数,每天一次,每周五次,以40-50 Gy的总剂量治疗总肿瘤体积,以30-40的总剂量治疗临床目标体积Gy。相比之下,B组的病变并未进行IMRT治疗分成亚病变,而是采用其他相同的方案,每次2 Gy /次,每周一次,每周五次,总剂量相同。对患者进行定期血液检查,肝功能检查,血清甲胎蛋白水平的测量以及肝脏造影剂磁共振成像(MRI)的随访。每3个月通过MRI评估治疗反应。结果显示,两组的总缓解率分别为82.9%和81.3%(P = 0.864)。交替性超分割放疗方案可提高生存率(P = 0.002)。两组的中位生存时间分别为9.7和6.5个月。两组的总6个月,1年,2年和3年生存率分别为62.9%和59.4%(P = 0.770),48.6和21.9%(P = 0.040),17.1和0.0%(P = 0.025)和2.9和0.0%(P = 1.000)。 B组的肝功能异常和放射性肝病的I-II程度高于A组(分别为P = 0.021和0.046)。此外,A组的放射性肝损伤发生率低于B组。因此,与传统的IMRT相比,交替超分割放疗治疗大规模HCC可以改善生活质量并延长总生存时间,暗示这是一种有效的辐射图。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号